Be this as it may, Vk*MYC and related models stand ready both to shed light on long-standing questions in myelomagenesis, such as the role of antigen and germinal center reentry of tumor precursors (187) and to revisit difficult issues in myeloma immunotherapy, such as the benefits of immune checkpoint inhibition (CPI) (188), which remain unclear at this juncture (189). Here, MYC is linked to neoplasm.